X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (124) 124
hematology (96) 96
aged (81) 81
female (79) 79
male (76) 76
middle aged (74) 74
myelodysplastic syndromes (71) 71
adult (70) 70
index medicus (67) 67
oncology (62) 62
aged, 80 and over (60) 60
prognosis (41) 41
adolescent (29) 29
hematology, oncology and palliative medicine (26) 26
myelodysplastic syndromes - genetics (24) 24
scoring system (24) 24
classification (23) 23
myelodysplastic syndrome (23) 23
retrospective studies (23) 23
survival rate (23) 23
myelodysplastic syndromes - mortality (21) 21
young adult (20) 20
myelodysplastic syndromes - therapy (19) 19
acute myeloid-leukemia (18) 18
cancer (18) 18
myelodysplastic syndromes - diagnosis (18) 18
myelodysplastic syndromes - drug therapy (18) 18
mds (17) 17
analysis (15) 15
myelodysplastic syndromes - epidemiology (15) 15
myelodysplastic syndromes - pathology (15) 15
risk factors (15) 15
survival (15) 15
treatment outcome (15) 15
antineoplastic agents - therapeutic use (14) 14
therapy (14) 14
hemic and lymphatic diseases (13) 13
iron chelating agents - therapeutic use (13) 13
leukemia (13) 13
mutation (13) 13
proposals (13) 13
survival analysis (13) 13
anemia (12) 12
care and treatment (12) 12
follow-up studies (12) 12
iron overload (12) 12
stem-cell transplantation (11) 11
azacitidine (10) 10
cells (10) 10
research (10) 10
deferasirox (9) 9
diagnosis (9) 9
germany - epidemiology (9) 9
labile plasma iron (9) 9
medicine & public health (9) 9
myelodysplastic syndromes - classification (9) 9
serum ferritin (9) 9
transfusion reaction (9) 9
valproic acid (9) 9
abridged index medicus (8) 8
anemia, sideroblastic - genetics (8) 8
antineoplastic agents (8) 8
azacitidine - therapeutic use (8) 8
bone-marrow (8) 8
chemotherapy (8) 8
imatinib mesylate (8) 8
myelodysplastic syndromes - complications (8) 8
pyrimidines - therapeutic use (8) 8
registries (8) 8
world health organization (8) 8
acute disease (7) 7
antimitotic agents (7) 7
benzamides (7) 7
blood transfusion (7) 7
comorbidity (7) 7
dna, mitochondrial - genetics (7) 7
drug therapy (7) 7
further section · weitere sektionen (7) 7
iron (7) 7
iron chelation (7) 7
iron chelation therapy (7) 7
iron overload - drug therapy (7) 7
iron overload - etiology (7) 7
myelodysplastic syndromes - blood (7) 7
oxidative stress (7) 7
point mutation (7) 7
prognostic scoring system (7) 7
refractory-anemia (7) 7
acute myeloid leukemia (6) 6
age (6) 6
antimetabolites, antineoplastic - therapeutic use (6) 6
antineoplastic agents - administration & dosage (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
case-control studies (6) 6
child (6) 6
clinical trials (6) 6
ferritin (6) 6
guidelines (6) 6
histone deacetylase inhibitors (6) 6
intensive chemotherapy (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Haematologica, ISSN 0390-6078, 10/2019, Volume 104, Issue 10, pp. 1912 - 1914
Journal Article
Blood, ISSN 0006-4971, 10/2016, Volume 128, Issue 15, pp. 1907 - 1908
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 3, pp. 223 - 232
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2010, Volume 16, Issue 1, pp. S30 - S36
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 23, pp. 2408 - 2417
The constitutively active BCR-ABL tyrosine kinase is the cause of chronic myeloid leukemia. Imatinib is the first small synthetic molecular inhibitor of the... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | MEDICINE, GENERAL & INTERNAL | CHRONIC GRANULOCYTIC-LEUKEMIA | INTERFERON-ALPHA | CHRONIC-PHASE | ABL TYROSINE KINASE | COMPLETE CYTOGENETIC REMISSION | PHILADELPHIA-CHROMOSOME | BLAST CRISIS | ALPHA PLUS CYTARABINE | Follow-Up Studies | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Fusion Proteins, bcr-abl - blood | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Cytarabine - administration & dosage | Interferon-alpha - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Benzamides | Protein-Tyrosine Kinases - antagonists & inhibitors | Dosage and administration | Chronic myeloid leukemia | Drug therapy | Interferon alpha | Clinical trials | Bone marrow | Transplants & implants | Pharmaceutical industry | Leukemia | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Haematologica, ISSN 0390-6078, 09/2012, Volume 97, Issue 9, pp. 1364 - 1371
Journal Article
Deutsches Arzteblatt, ISSN 0012-1207, 07/2009, Volume 106, Issue 30, pp. 499 - 504